Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer
CompanyDeals

Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025
CompanyDrug

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Harbin Gloria Partners with Eisai to Promote Methycobal in China
CompanyDeals

Harbin Gloria Partners with Eisai to Promote Methycobal in China

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler
CompanyDrug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
CompanyDrug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Hansoh Pharma's Almonertinib Approved in UK for EGFR-Mutated NSCLC
CompanyDrug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years
CompanyMedical Device

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025
CompanyDrug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

EU Approves Pfizer and Takeda's Adcetris in Hodgkin Lymphoma Combination Regimen
CompanyDrug

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer
CompanyDrug

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline
CompanyDeals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors
CompanyDeals

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors